Multigene Assay for Prognosis of Renal Cancer
    8.
    发明申请
    Multigene Assay for Prognosis of Renal Cancer 审中-公开
    多基因测定肾癌预后

    公开(公告)号:US20160230234A1

    公开(公告)日:2016-08-11

    申请号:US15022917

    申请日:2014-09-17

    Abstract: A method of making a prognosis as to whether a patient having renal cancer is like to survive in a tumour tissue sample obtained from the patient is provided. The method comprising determining the level of expression for each marker of a panel of markers comprising at least one housekeeping gene selected from the group consisting of ACTB, RPL13A, RPL9, and RPS29 and any combinations thereof and at least one prognostic gene selected from the group consisting of CXCL5, EFNA5, EMCN, G6PC, GFPT2, HIST2H3C, IGFBP1, LAMB3, MMP9, MOCOS, PLG, PRAME, RARRES1, SDPR, SLC6A19, TK1, KDELR3 and TSPAN7 and any combinations thereof, comparing the level of expression of each marker with a predetermined reference level associated with each marker, and determining the differential expression of each marker in the tumour tissue sample based on the expression parameter for each marker to provide a prognosis for renal cancer.

    Abstract translation: 提供了一种关于患有肾癌的患者是否希望在从患者获得的肿瘤组织样品中存活的预后的方法。 所述方法包括确定包含至少一种选自ACTB,RPL13A,RPL9和RPS29及其任何组合的至少一个持家基因的标志物组的每个标志物的表达水平和至少一种选自下组的预后基因 由CXCL5,EFNA5,EMCN,G6PC,GFPT2,HIST2H3C,IGFBP1,LAMB3,MMP9,MOCOS,PLG,PRAME,RARRES1,SDPR,SLC6A19,TK1,KDELR3和TSPAN7及其任何组合组成,比较每个标志物的表达水平 具有与每个标记相关联的预定参考水平,并且基于每个标记物的表达参数确定肿瘤组织样品中每个标记物的差异表达以提供肾癌的预后。

Patent Agency Ranking